File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)

Article: The impact of the multi-disciplinary molecular tumour board and integrative next generation sequencing on clinical outcomes in advanced solid tumours

TitleThe impact of the multi-disciplinary molecular tumour board and integrative next generation sequencing on clinical outcomes in advanced solid tumours
Authors
KeywordsMolecular tumour board
Next-generation sequencing
Precision oncology
Sequence-directed therapy
Issue Date28-Apr-2023
PublisherElsevier
Citation
The Lancet Regional Health - Western Pacific, 2023, v. 36 How to Cite?
Abstract

Background: The integration of next-generation sequencing (NGS) comprehensive gene profiling (CGP) into clinical practice is playing an increasingly important role in oncology. Therefore, the HKU-HKSH Multi-disciplinary Molecular Tumour Board (MTB) was established to advance precision oncology in Hong Kong. A multicenter retrospective study investigated the feasibility of the HKU-HKSH MTB in determining genome-guided therapy for treatment-refractory solid cancers in Hong Kong.

Methods: Patients who were presented at the HKU-HKSH MTB between August 2018 and June 2022 were included in this study. The primary study endpoints were the proportion of patients who receive MTB-guided therapy based on genomic analysis and overall survival (OS). Secondary endpoints included the proportion of patients with actionable genomic alterations, objective response rate (ORR), and disease control rate (DCR). The Kaplan–Meier method was used in the survival analyses, and hazard ratios were calculated using univariate Cox regression.

Findings: 122 patients were reviewed at the HKU-HKSH MTB, and 63% (n = 77) adopted treatment per the MTB recommendations. These patients achieved a significantly longer median OS than those who did not receive MTB-guided therapy (12.7 months vs. 5.2 months, P = 0.0073). Their ORR and DCR were 29% and 65%, respectively.

Interpretation: Our study demonstrated that among patients with heavily pre-treated advanced solid cancers, MTB-guided treatment could positively impact survival outcomes, thus illustrating the applicability of NGS CGPs in real-world clinical practice.

Funding: The study was supported by the Li Shu Pui Medical Foundation. Dr Aya El Helali was supported by the Li Shu Pui Medical Foundation Fellowship grant from the Li Shu Pui Medical Foundation. Funders had no role in study design, data collection, data analysis, interpretation, or writing of the report.


Persistent Identifierhttp://hdl.handle.net/10722/331048
ISSN
2023 Impact Factor: 7.6
2023 SCImago Journal Rankings: 2.197
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorEl Helali, A-
dc.contributor.authorLam, TC-
dc.contributor.authorKo, EYL-
dc.contributor.authorShih, DJH-
dc.contributor.authorChan, CK-
dc.contributor.authorWong, CHL-
dc.contributor.authorWong, JWH-
dc.contributor.authorCheung, LWT-
dc.contributor.authorLau, JKS-
dc.contributor.authorLiu, APY-
dc.contributor.authorChan, ASY-
dc.contributor.authorLoong, HH-
dc.contributor.authorLam, STS-
dc.contributor.authorChan, GCF-
dc.contributor.authorLee, VHF-
dc.contributor.authorYuen, KK-
dc.contributor.authorNg, WT-
dc.contributor.authorLee, AWM-
dc.contributor.authorMa, ESK-
dc.date.accessioned2023-09-21T06:52:20Z-
dc.date.available2023-09-21T06:52:20Z-
dc.date.issued2023-04-28-
dc.identifier.citationThe Lancet Regional Health - Western Pacific, 2023, v. 36-
dc.identifier.issn2666-6065-
dc.identifier.urihttp://hdl.handle.net/10722/331048-
dc.description.abstract<p>Background: The integration of next-generation sequencing (NGS) comprehensive gene profiling (CGP) into clinical practice is playing an increasingly important role in oncology. Therefore, the HKU-HKSH Multi-disciplinary Molecular Tumour Board (MTB) was established to advance precision oncology in Hong Kong. A multicenter retrospective study investigated the feasibility of the HKU-HKSH MTB in determining genome-guided therapy for treatment-refractory solid cancers in Hong Kong. <br></p><p>Methods: Patients who were presented at the HKU-HKSH MTB between August 2018 and June 2022 were included in this study. The primary study endpoints were the proportion of patients who receive MTB-guided therapy based on genomic analysis and overall survival (OS). Secondary endpoints included the proportion of patients with actionable genomic alterations, objective response rate (ORR), and disease control rate (DCR). The Kaplan–Meier method was used in the survival analyses, and hazard ratios were calculated using univariate Cox regression. <br></p><p>Findings: 122 patients were reviewed at the HKU-HKSH MTB, and 63% (n = 77) adopted treatment per the MTB recommendations. These patients achieved a significantly longer median OS than those who did not receive MTB-guided therapy (12.7 months vs. 5.2 months, P = 0.0073). Their ORR and DCR were 29% and 65%, respectively. <br></p><p>Interpretation: Our study demonstrated that among patients with heavily pre-treated advanced solid cancers, MTB-guided treatment could positively impact survival outcomes, thus illustrating the applicability of NGS CGPs in real-world clinical practice. <br></p><p>Funding: The study was supported by the Li Shu Pui Medical Foundation. Dr Aya El Helali was supported by the Li Shu Pui Medical Foundation Fellowship grant from the Li Shu Pui Medical Foundation. Funders had no role in study design, data collection, data analysis, interpretation, or writing of the report.</p>-
dc.languageeng-
dc.publisherElsevier-
dc.relation.ispartofThe Lancet Regional Health - Western Pacific-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectMolecular tumour board-
dc.subjectNext-generation sequencing-
dc.subjectPrecision oncology-
dc.subjectSequence-directed therapy-
dc.titleThe impact of the multi-disciplinary molecular tumour board and integrative next generation sequencing on clinical outcomes in advanced solid tumours-
dc.typeArticle-
dc.identifier.doi10.1016/j.lanwpc.2023.100775-
dc.identifier.scopuseid_2-s2.0-85154602050-
dc.identifier.volume36-
dc.identifier.isiWOS:001071085100001-
dc.identifier.issnl2666-6065-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats